Talphera (TLPH) EBITDA Margin Growth (5y) (2016 - 2025)
Powered by 
Analysis
Talphera (TLPH) EBITDA Margin Growth (5y) (2016 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Talphera | 92.90 Mn | 92.90 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -34.15 Mn |
| Mar 31, 2025 | -669,430.00 |
| Dec 31, 2023 | 26,650.00 |
| Sep 30, 2023 | -35,393.00 |
| Jun 30, 2023 | -69,432.00 |
| Mar 31, 2022 | -164,674.00 |
| Dec 31, 2021 | -40.86 Mn |
| Sep 30, 2021 | -22,671.00 |
| Jun 30, 2021 | -207,705.00 |
| Mar 31, 2021 | -150,732.00 |
| Dec 31, 2020 | -81,697.00 |
| Sep 30, 2020 | -70,665.00 |
| Jun 30, 2020 | 18,847.00 |
| Mar 31, 2020 | 219,264.00 |
| Dec 31, 2019 | 205,574.00 |
| Sep 30, 2019 | -212,093.00 |
| Jun 30, 2019 | 1.51 Mn |
| Mar 31, 2019 | 384,538.00 |
| Dec 31, 2018 | -180,351.00 |
| Sep 30, 2018 | -102,135.00 |